Improved midkine antibody
AssigneeCellmid Limited
InventorsMaria Halasz, Darren Jones, Nico Martens, Phillip Cunnah
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to isolated or recombinant proteins, such as antibodies, which bind to, and inhibit or reduce the function of, midkine (MK) and their use as therapeutic and/or diagnostic agents for midkine-related disorders. The present disclosure is also related to nucleic acid sequences which encode said proteins and their expression in recombinant host cells. In particular, the present disclosure is directed towards humanized antibodies derived from murine antibody IP14 which specifically bind to human MK.
Claims43
A substantially purified and/or recombinant antibody comprising:
- (i) an immunoglobulin heavy chain comprising a variable region comprising an amino acid sequence having 95% identity to a sequence set forth in SEQ ID NO:
- 8, wherein residue at position 16 is G or H, residue at position 43 is Q or K, residue at positions 71 and 78 is S or T, and residue at position 75 is S or A;
- and/or
- (ii) an immunoglobulin light chain comprising a variable region comprising an amino acid sequence having 95% identity to a sequence set forth in SEQ ID NO:
- 17,
- wherein the antibody binds human midkine (huMK) protein.
A method for inhibiting an interaction between human midkine and a ligand thereof in a cell, said method comprising exposing the cell to an antibody according to any one of claims 1 to 8 or a conjugate according to any one of claims 9 to 14 or a pharmaceutical composition according to any one of claims 25 to 20.
A method for inhibiting human midkine activity in a cell, said method comprising exposing the cell to an antibody according to any one of claims 1 to 8 or a conjugate according to any one of claims 9 to 14 or a pharmaceutical composition according to any one of claims 25 to 20.
A method for treating or preventing a midkine-related disease or disorder in a subject in need thereof, said method comprising administering to the subject an antibody according to any one of claims 1 to 8 or a conjugate according to any one of claims 9 to 14 or a pharmaceutical composition according to any one of claims 25 to 20.
Dependencies are inferred from the claim text.